Antibiotic combination as empirical therapy for extended spectrum beta-lactamase

Oman Medical Journal

Volumn 23, Issue 2, 2008, Pages 78-81

  Al Muharrmi, Zakariya ^a   Rafay, Akbar ^a   Balkhair, Abdullah ^a   Jabri, Ali A ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

Combination therapy; Empirical therapy; Extended spectrum lactamases (ESBLs)

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; DISK DIFFUSION; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; ZONE OF INHIBITION;

EID: 84995524616     PISSN: 1999768X     EISSN: 20705204     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Goldstein FW. Combating resistance in a challenging, changing environment. Clin Microbiol Infect 2007 Jun;13(Suppl 2):2-6.
2. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical implications of extended spectrum ⊠-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect 2005 Oct;51(3):211-217.
3. Stürenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003 Nov;47(4):273-295.
4. Sorlózano A, Gutiérrez J, de Dios Luna J, Oteo J, Liébana J, Soto MJ, et al. High presence of extended-spectrum ⊠-lactamases and resistance to quinolones in clinical isolates of Escherichia coli. Microbiol Res 2007;162(4):347-354.
5. Jacoby GA, Munoz-Price LS. The new ⊠-lactamases. N Engl J Med 2005 Jan;352(4):380-391.
6. Ramphal R, Ambrose PG. Extended-spectrum ⊠-lactamases and clinical outcomes: current data. Clin Infect Dis 2006 Apr;42(Suppl 4):S164-S172.
7. Drieux L, Brossier F, Sougakoff W, Jarlier V. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide. Clin Microbiol Infect 2008 Jan;14(Suppl 1):90-103.
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne, PA: CLSI, 2005.
9. Carter MW, Oakton KJ, Warner M, Livermore DM. Detection of extended-spectrum beta-lactamases in klebsiellae with the Oxoid combination disk method. J Clin Microbiol 2000 Nov;38(11):4228-4232.
10. M’Zali FH, Chanawong A, Kerr KG, Birkenhead D, Hawkey PM. Detection of extended-spectrum beta-lactamases in members of the family enterobacteriaceae: comparison of the MAST DD test, the double disc and the Etest ESBL. J Antimicrob Chemother 2000 Jun;45(6):881-885.
11. Stürenburg E, Sobottka I, Feucht HH, Mack D, Laufs R. Comparison of BDPhoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum beta-lactamase detection in Escherichia coli and Klebsiella species clinical isolates. Diagn Microbiol Infect Dis 2003 Jan;45(1):29-34.
12. Doménech-Sánchez A, Pascual A, Suárez AI, Alvarez D, Benedí VJ, Martínez-Martínez L. Activity of nine antimicrobial agents against clinical isolates of Klebsiella pneumoniae producing extended-spectrum ⊠-lactamases and deficient or not in porins. J Antimicrob Chemother 2000 Nov;46(5):858-859.
13. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum ⊠-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000 Mar;30(3):473-478.
14. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum ⊠-lactamase-and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 2005 Dec;53(4):257-264.
15. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998 Oct;280(14):1233-1237.
16. Masterton RG, Turner PJ. Trends in antimicrobial susceptibility in UK centres: the MYSTIC Programme (1997-2002). Int J Antimicrob Agents 2006 Jan;27(1):69-72.
17. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000 Feb;45(2):183-189.
18. Kizirgil A, Demirdag K, Ozden M, Bulut Y, Yakupogullari Y, Toraman ZA. In vitro activity of three different antimicrobial agents against ESBL producing Escherichia coli and Klebsiella pneumoniae blood isolates. Microbiol Res 2005;160(2):135-140.